Inhaled vasodilator therapy in acute lung injury: first, do NO harm?

The acute respiratory distress syndrome in adults (ARDS) is defined by refractory hypoxaemia in the presence of radiographic evidence of bilateral pulmonary infiltrates. The ARDS syndrome and lesser degrees of acute lung injury (ALI) are characterised by the presence of high permeability alveolar oedema, a loss of hypoxic pulmonary vasoconstriction (HPV) leading to a marked increase in ventilation-perfusion mismatch, and increased pulmonary vascular resistance (PVR). Adverse changes in ventilation-perfusion account almost wholly for the hypoxaemia that characterises ALI/ARDS and the rise in PVR is commonly associated with clinically significant right ventricular dysfunction leading, in turn, to preload limitation, sepsis, and impaired left ventricular performance. The detrimental effects on cardiac performance almost certainly contribute to morbidity and, in some patients, mortality.

The capacity of conventional vasodilator therapy to influence these events remains limited and this approach is plagued with difficulties. Firstly, non-specific vasodilation has a global pulmonary effect, abolishing any remaining hypoxic pressor response and causing a further deterioration in ventilation-perfusion. Secondly, doses required to produce a beneficial effect on the pulmonary vasculature frequently induce systemic vasodilatation and cardiovascular instability. Nevertheless, several such agents have been employed and none have emerged as universally efficacious. Nitrate vasodilators, calcium channel blockers, and the vasodilator eicosanoids have all been used in ALI/ARDS, the latter provoking interest because of the association with beneficial effects, such as improved cardiac performance, tissue perfusion, and platelet disaggregation.

In this context, the issues are complex in that oxygen delivery to respiring tissues may be increased by such agents through improvements in cardiac performance consequent upon reduced afterload, despite falls in arterial oxygen tension occasioned by worsening shunt.

Given that the discovery of a pharmacologically distinct receptor population in the pulmonary circulation has proved elusive, investigators have attempted to manipulate PVR in patients with lung injury using agents with particular pharmacological or physical properties. For example, a rapidly metabolised drug with a very short half-life administered intravenously may no longer possess biological activity by the time it reaches the systemic circulation. Thus, adenosine has been shown to have a vasodilator effect specific to the pulmonary circulation when infused into patients with primary pulmonary hypertension, but in biventricular failure it induces significant increases in pulmonary artery occlusion pressure, suggesting a negative effect on ventricular diastolic performance which would clearly be unhelpful in patients with cardiac function compromised by ALI/ARDS.

By contrast, the use of inhaled vasodilators is theoretically doubly attractive. Any lack of pharmacological specificity for the pulmonary circulation becomes less relevant, provided that agents are inactivated by the time the systemic circulation is reached. If the action of such drugs is confined to the area of deposition, then blood will be recruited to lung units to which the inspired gas has access, thereby reducing shunt fraction and PVR. To date, most laboratory and clinical experience has been gained in ALI/ARDS using inhaled nitric oxide (NO). An increasing body of clinical evidence suggests that the theoretical advantages outlined above are borne out in practice, with beneficial reductions in PVR and improvements in gas exchange.

In 1993 Rossaint et al published the results of a small study of nine patients with ARDS. Nitric oxide, 18 ppm, was administered by inhalation for 40 minutes, producing a significant reduction in the mean pulmonary artery pressure, and an increase in the Pao/Fio ratio. The mean shunt fraction was reduced significantly from 36% to 31%. Seven patients were subsequently treated with inhaled NO for 3-53 days during which time the investigators were able to reduce the inspired oxygen concentration by 15%. They did not observe any adverse systemic haemodynamic consequences. By contrast, infusion of intravenous prostanilcin caused an increase in shunt and a reduction in systemic arterial pressures.

Similar findings have been reported in similar patients using inhaled NO at considerably lower concentrations. Furthermore, NO at 2 ppm completely reversed the increase in PVR associated with the hypercapnia resulting from low frequency ventilation, a technique commonly employed in the management of ARDS. Moreover, this modest dose of NO produced beneficial effects on gas exchange.

However, not all patients seem to benefit from NO inhalation and no firm data have emerged to suggest that it causes a significant reduction in ARDS-associated mortality. This may not be altogether surprising since such patients tend to die from the associated underlying disease or the twin complications of sepsis and multiple organ failure. Survival may therefore be an insensitive end point, and the achievement of physiological goals or reduced morbidity/ventilator time may represent more appropriate targets for controlled trials.

Nevertheless, the encouraging preliminary results reported with administration of NO by inhalation to patients with ALI/ARDS have led to widespread uncontrolled use of this potentially exciting therapy. The logistics of its safe administration are complex. NO reacts with oxygen to form nitrogen dioxide which dissolves to form toxic nitrous acid. The reaction rate is dependent upon the available oxygen concentration, so the time it spends in combination with high concentrations of oxygen must be kept to a minimum. There are a number of ventilator circuits which have been designed specifically to overcome this problem, and simple nitrogen dioxide fuel cell analysers are available which should also contribute to patient monitoring and therefore safety.

However, the drug remains unlicensed and there is no standardised protocol of administration nor formalised means of monitoring systems of administration. Furthermore, the assumption that the evanescence of NO equates to a benign local action is almost certainly an oversimplification. NO reacts rapidly with haemoglobin and is therefore carried from the lung into the systemic...
circuit, albeit in modified form. Knowledge of the physiology of NO derivatives in animal models is increasing rapidly and providing contradictory results.

The most frequently quoted toxicology studies describe experiments in which non-diseased animals are exposed to inhaled NO. Exposure of rats to 1000 ppm NO for 30 minutes, 20 exposure of rabbits to 43 ppm for six days, and long term studies (six months) in mice have not demonstrated histological, ultrastructural, or gravimetric evidence of pulmonary toxicity. Unfortunately, such investigations provide no guide to possible toxic effects in diseased lungs with ongoing inflammatory processes and cannot therefore be regarded as totally reassuring. Furthermore, rabbits inhaling 30 ppm NO for 15 minutes displayed significantly prolonged bleeding times, and 300 ppm significantly reduced systemic arterial pressures. 23

The availability of NO synthase (NOS) antagonists, such as N^6^-monomethyl-L-arginine (L-NMMA), has enabled scientists to investigate the role of endogenous NO in a variety of physiological and pathological systems. In ALI/ARDS, macrophages and activated neutrophils are recruited to the lung2, 125 where they release reactive oxygen species (ROS). 26, 22 Hydrogen peroxide and nitrotyrosine, markers of ROS activity, have been detected in breath condensate 29 and lung tissue, 29 respectively, from patients with ARDS. Furthermore, endotoxaemia stimulates the expression of the messenger RNA for the calcium-independent, inducible isofrom of NOS (iNOS) in rats. 30 In pathological states there may therefore be a secondary increase in NO generation. There is increasing evidence to suggest that NO may be an effect scavenger of ROS 31 and may inhibit xanthine oxidase, 32 an enzyme which produces superoxide. In this sense NO may be cytoprotective. By contrast, under hypoxic conditions NO reacts with superoxide to form peroxynitrite 33 which is profoundly cytotoxic. This reaction occurs three times faster than the scavenging of superoxide by the antioxidant superoxide dismutase. The exact nature of peroxynitrite toxicity is emerging slowly, but it may be responsible for surfactant damage and be directly injurious to proteins, 34 producing nitrotyrosine residues. These have been detected in both animal models and in lung tissue from patients with ARDS. 29 In addition, peroxynitrite appears to inhibit metab- molic processes in type II alveolar cells. The dysfunctional nature of surfactant in ARDS is well established and has been comprehensively reviewed elsewhere. 36

The interrelationship of NO, superoxide, and peroxynitrite in the context of lipid peroxidation has been explored in vitro, 37 the investigators concluding that NO can both stimulate superoxide/peroxide/hydroxyl-induced lipid oxidation and also mediate antioxidant protective re- actions at higher rates of NO production. The pro-oxidant versus antioxidant outcome is thus critically dependent on relative concentrations of individual reactive species. They suggest a mechanism by which, under certain conditions, NO could terminate propagating lipid peroxidation chain reactions through a reaction with lipid peroxyl inter- mediates.

The biology of NO is therefore complicated and its actions seem to depend upon prevailing conditions. In ARDS the lung is likely to be primed to produce both endogenous NO and superoxide. The inspired oxygen concentration will be high, which may in itself be toxic. Inhaled NO may scavenge toxic radical species and term- inate propagating chain reactions, but may equally combine with superoxide to form the toxic peroxynitrite. Chronic hypoxia may lead to a downregulation of second messenger activation in vascular smooth muscle, reducing the vasodilator effect of exogenous NO. 30 If the patient then receives NO by inhalation at 20 ppm, a concentration several orders of magnitude greater than the estimated concentration of endogenous NO in alveolar gas, per- oxynitrite levels may increase and fuel oxidant-mediated inflammation.

Infants with severe congenital heart disease, 35 persistent fetal circulation, 36 and diaphragmatic hernia 37 often suffer considerable morbidity and mortality due to severe pul- monary hypertension. For these patients the issues may be different: they may die because of cardiac impairment consequent upon elevated PVR and the chance to control the circulation with NO may considerably increase their changes of survival. An enlarging literature supports this indication for inhaled NO therapy where different risk- benefit equations may apply. Nitric oxide improves gas exchange and reduces PVR in some patients with ARDS, an attractive option in a condition desperately short of effective therapeutic interven- tions. For some this may mean the difference be- tween survival and non-survival, and rapid growth in the (largely) unmonitored use of inhaled NO is under- standable. However, the potential for harmful side effects may emerge increasingly as our understanding of the biology of NO increases. In this sense the principle of primum non nocere should not be forgotten. The in- formation to allow a reasoned risk-benefit analysis of NO therapy may be extremely hard to obtain, but hopefully will be forthcoming.
Inhaled vasodilator therapy in acute lung injury: first, do NO harm?


21 Hugod C. Effect of exposure to 43 ppm nitric oxide and 3-6 ppm nitrogen dioxide on rabbit lung. *Int Arch Occup Environ Health* 1979;42:159-67.


33 Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci USA* 1990;87:1620-4.


Inhaled vasodilator therapy in acute lung injury: first, do NO harm?

S J Brett and T W Evans

Thorax 1995 50: 821-823
doi: 10.1136/thx.50.8.821

Updated information and services can be found at:
http://thorax.bmj.com/content/50/8/821.citation

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/